These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 25253621)

  • 1. Association of apixaban therapy and prothrombin time in patients with atrial fibrillation.
    Kanemoto M; Kuhara H; Ueda T; Shinohara T; Oda T; Nakao F; Kamei T; Ikeda Y; Fujii T
    Circ J; 2014; 78(11):2651-6. PubMed ID: 25253621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coagulation markers in patients with venous thromboembolism treated with 10 mg apixaban twice daily.
    Ono R; Fukushima K; Yamazaki T; Yamashita D; Takahashi H; Hori Y; Nishimura K
    Naunyn Schmiedebergs Arch Pharmacol; 2022 Feb; 395(2):159-166. PubMed ID: 34851448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement of Anti-Factor Xa Activity in Patients on Apixaban for Non-Valvular Atrial Fibrillation.
    Osanai H; Ajioka M; Masutomi T; Kuwayama T; Ishihama S; Sakamato Y; Otaka N; Sakaguchi T; Inoue Y; Kanbara T; Nakashima Y; Asano H; Sakai K
    Circ J; 2015; 79(12):2584-90. PubMed ID: 26439323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Responses of prothrombin time and activated partial thromboplastin time to edoxaban in Japanese patients with non-valvular atrial fibrillation: characteristics of representative reagents in Japan (CVI ARO 7).
    Suzuki S; Morishima Y; Takita A; Yagi N; Otsuka T; Arita T; Yamashita T
    Heart Vessels; 2019 Dec; 34(12):2011-2020. PubMed ID: 31123819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apixaban Levels in Octogenarian Patients with Non-valvular Atrial Fibrillation.
    Nissan R; Spectre G; Hershkovitz A; Green H; Shimony S; Cooper L; Nakav S; Shochat T; Grossman A; Fuchs S
    Drugs Aging; 2019 Feb; 36(2):165-177. PubMed ID: 30460518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Anti-factor Xa Activity Among Three Different Factor Xa Inhibitors in Non-valvular Atrial Fibrillation Patients with Renal Impairment.
    Tobe A; Osanai H; Tanaka A; Sakaguchi T; Kambara T; Nakashima Y; Asano H; Ishii H; Ajioka M; Murohara T
    Clin Drug Investig; 2020 Jun; 40(6):567-573. PubMed ID: 32314297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A study on indices of apixaban anticoagulation: A single-center prospective study.
    Komiyama M; Miyazaki Y; Wada H; Iguchi M; Abe M; Ogawa H; Akao M; Yamakage H; Satoh-Asahara N; Sunagawa Y; Morimoto T; Hasegawa K
    J Pharmacol Sci; 2018 Jun; 137(2):105-109. PubMed ID: 29866521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laboratory measurement of apixaban using anti-factor Xa assays in acute ischemic stroke patients with non-valvular atrial fibrillation.
    Shin H; Cho MC; Kim RB; Kim CH; Choi NC; Kim SK; Koh EH
    J Thromb Thrombolysis; 2018 Feb; 45(2):250-256. PubMed ID: 29198080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Effectiveness and Safety of Apixaban and Vitamin K Antagonist Therapy in Patients With Nonvalvular Atrial Fibrillation Treated in Routine German Practice.
    Coleman CI; Peacock WF; Antz M
    Heart Lung Circ; 2018 Mar; 27(3):390-393. PubMed ID: 28528780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical implications of assessment of apixaban levels in elderly atrial fibrillation patients: J-ELD AF registry sub-cohort analysis.
    Suzuki S; Yamashita T; Akao M; Okumura K;
    Eur J Clin Pharmacol; 2020 Aug; 76(8):1111-1124. PubMed ID: 32451850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large healthcare system.
    Villines TC; Ahmad A; Petrini M; Tang W; Evans A; Rush T; Thompson D; Oh K; Schwartzman E
    Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):80-90. PubMed ID: 30500885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillation.
    Skeppholm M; Al-Aieshy F; Berndtsson M; Al-Khalili F; Rönquist-Nii Y; Söderblom L; Östlund AY; Pohanka A; Antovic J; Malmström RE
    Thromb Res; 2015 Jul; 136(1):148-53. PubMed ID: 25981142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apixaban in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: Rationale and design of the PAROS cross-sectional study.
    Picard F; Ducrocq G; Danchin N; Falissard B; Hanon O; Mahe I; Touzé E; Steg PG
    Arch Cardiovasc Dis; 2018 May; 111(5):349-356. PubMed ID: 29191525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rivaroxaban in clinical practice for atrial fibrillation with special reference to prothrombin time.
    Suzuki S; Otsuka T; Sagara K; Kano H; Matsuno S; Kato Y; Takai H; Uejima T; Oikawa Y; Nagashima K; Kirigaya H; Yajima J; Sawada H; Aizawa T; Yamashita T
    Circ J; 2014; 78(3):763-6. PubMed ID: 24451650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet Aggregation in Direct Oral Factor Xa Inhibitors-treated Patients With Atrial Fibrillation: A Pilot Study.
    Bánovčin P; Škorňová I; Samoš M; Schnierer M; Bolek T; Kovář F; Staško J; Kubisz P; Mokáň M
    J Cardiovasc Pharmacol; 2017 Oct; 70(4):263-266. PubMed ID: 28708713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care.
    Gulilat M; Keller D; Linton B; Pananos AD; Lizotte D; Dresser GK; Alfonsi J; Tirona RG; Kim RB; Schwarz UI
    J Thromb Thrombolysis; 2020 Feb; 49(2):294-303. PubMed ID: 31564018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of newly-developed modified diluted prothrombin time reagent in non-valvular atrial fibrillation patients with direct oral anticoagulants: A comparative study with conventional reagents.
    Kumano O; Suzuki S; Yamazaki M; An Y; Yasaka M; Ieko M;
    Int J Lab Hematol; 2023 Feb; 45(1):119-125. PubMed ID: 36114152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics of Apixaban-Treated Patients, Evaluation of the Dose Prescribed, and the Persistence of Treatment: A Cohort Study in Catalonia.
    Gomez-Lumbreras A; Cortes J; Giner-Soriano M; Quijada-Manuitt MA; Morros R
    J Cardiovasc Pharmacol Ther; 2018 Nov; 23(6):494-501. PubMed ID: 29792125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors for a high apixaban level in elderly patients with atrial fibrillation prescribed reduced dose of apixaban.
    Suzuki S; Yamashita T; Akao M; Okumura K
    Eur J Clin Pharmacol; 2021 Nov; 77(11):1757-1758. PubMed ID: 34014337
    [No Abstract]   [Full Text] [Related]  

  • 20. Interpatient Variation in Rivaroxaban and Apixaban Plasma Concentrations in Routine Care.
    Gulilat M; Tang A; Gryn SE; Leong-Sit P; Skanes AC; Alfonsi JE; Dresser GK; Henderson SL; Rose RV; Lizotte DJ; Teft WA; Schwarz UI; Tirona RG; Kim RB
    Can J Cardiol; 2017 Aug; 33(8):1036-1043. PubMed ID: 28754389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.